Company Description
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease.
The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease.
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy.
The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases.
The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.
Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | David Stamler |
Contact Details
Address: 500 Collins Street, Level 15 Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9349 4906 |
| Website | alteritytherapeutics.com |
Stock Details
| Ticker Symbol | ATHE |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 1131343 |
| CUSIP Number | 02155X205 |
| ISIN Number | US02155X2053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David A. Stamler M.D. | Chief Executive Officer and Director |
| Abby Macnish Niven B.Com., B.Sc., C.F.A. | Chief Financial Officer and Company Secretary |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research and Development Advisory Board |
| Dr. Steven D. Targum M.D. | Chief Medical Advisor |
| Dr. Robert Cherny | Head of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 8, 2026 | 6-K | Report of foreign issuer |
| Sep 8, 2026 | 6-K | Report of foreign issuer |
| Sep 3, 2026 | 6-K | Report of foreign issuer |
| Sep 2, 2026 | 6-K | Report of foreign issuer |
| Sep 2, 2026 | 6-K | Report of foreign issuer |
| Sep 1, 2026 | 6-K | Report of foreign issuer |
| Aug 31, 2026 | 6-K | Report of foreign issuer |
| Aug 31, 2026 | 6-K | Report of foreign issuer |
| Aug 28, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Aug 28, 2026 | 6-K | Report of foreign issuer |